V Bryan Lawlis

CIK 1247681 · last filed 2025-05-22

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.89M

Companies

Total Filings

Lifetime Open-Market Net

-$9.50M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

BMRN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers

BIOMARIN PHARMACEUTICAL INC — 50 joint filings, latest 2024-05-30

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
GERN	Director	13,300	$1.13	$15.0K	-$220.6K	16	2025-05-22
BMRN	Director	33,140	$56.63	$1.88M	-$9.28M	45	2023-05-24
Spyre Therapeutics, Inc. (AGLE) Delisted	Director	—	$12.01	—	$0	5	2022-06-09
CHRS	Director	—	$1.05	—	$0	10	2021-01-13
STRO	Director	—	$10.29	—	$0	1	2018-09-27
HUMANIGEN, INC (KBIO) Delisted	Director	—	—	—	$0	1	2013-09-03

Recent Filings · Page 3 of 9

81 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2021-02-18	BMRN	Mixed	—	-$456.9K	EDGAR
2021-01-13	CHRS	Grant (A)	—	$0	EDGAR
2020-06-10	Spyre Therapeutics, Inc. (AGLE) Delisted	Grant (A)	—	$0	EDGAR
2020-06-09	BMRN	Sell (S)	−4,430	-$476.0K	EDGAR
2020-06-09	GERN	Grant (A)	—	$0	EDGAR
2020-05-29	BMRN	Grant (A)	+4,300	$0	EDGAR
2020-03-18	BMRN	Mixed	−4,610	-$554.8K	EDGAR
2020-01-14	CHRS	Grant (A)	—	$0	EDGAR
2019-12-19	BMRN	Mixed	—	-$231.9K	EDGAR
2019-09-18	BMRN	Mixed	—	-$198.6K	EDGAR

Showing 21–30 of 81

Prev Page 3 of 9 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.